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With the growing use of selective serotonin reuptake inhibitor medications (SSRIs) 
for the treatment of depression during the perinatal period, questions have been raised 
about the longterm impact of these medications on development. We aimed to 
investigate how developmental SSRI exposure may alter affect-related behaviors and 
associated molecular processes in offspring using a rodent model of maternal stress 
and depression. For this purpose, prenatally stressed or non-stressed male offspring 
were exposed to fluoxetine (5 mg/kg/day) or vehicle, via lactation, until weaning. 
Primary results show that postnatal fluoxetine exposure differentially altered anxiety-
like behavior by increasing anxiety in non-stressed offspring and decreasing anxiety 
in prenatally stressed offspring. In the hippocampus, developmental fluoxetine 
exposure decreased BDNF IV and TrkB mRNA expression. Prenatal stress alone also 
decreased escape behaviors and decreased hippocampal BDNF IV mRNA expression. 
These data provide important evidence for the long-term programming effects of 
early-life exposure to SSRIs on brain and behavior.  
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Introduction 
Selective serotonin reuptake inhibitor medications (SSRIs) are the treatment of choice 
for mood disorders during pregnancy and the postpartum period, with up to 10% of 
pregnant women being prescribed these medications (Cooper, Willy, Pont, & Ray, 
2007; Oberlander, Warburton, Misri, Aghajanian, & Hertzman, 2006). SSRIs have 
relatively few side effects for the mother and are not associated with gross teratogenic 
effects in offspring (Kiryanova, McAllister, & Dyck, 2013; Malm, 2012). However, 
SSRIs cross the placental barrier, are evident in the umbilical cord blood, and are 
present in breast milk (Homberg, Schubert, & Gaspar, 2010; Kristensen et al., 1999; 
Rampono, Proud, Hackett, Kristensen, & Ilett, 2004) and recent clinical studies report 
that neonates exposed to SSRIs during gestation have an increased risk for 
complications at birth involving low birth weight, reduced gestational age, and 
impaired heart rate variability (Moses-Kolko et al., 2005; Oberlander, Gingrich, & 
Ansorge, 2009). In addition, clinical reports in infants also show that prenatal 
exposure to SSRIs may affect neurodevelopment as evidenced by alterations in 
S100B levels (Pawluski, Galea, Brain, Papsdorf, & Oberlander, 2009), the 
serotonergic system functioning (Laine, Heikkinen, Ekblad, & Kero, 2003), as well as 
a changes in the hypothalamic-pituitary-adrenal (HPA) system (Oberlander, et al., 
2009; Pawluski et al., 2012).  
Although there is limited clinical insight in the long-term outcomes of 
developmental exposure to SSRIs on mood disorders in adulthood, prenatal exposure 
to SSRIs can impact affect-related behaviors in children (Misri et al., 2006; 
Oberlander et al., 2010; Oberlander et al., 2007). For example, 4 year old children, 
exposed prenatally to SSRIs, have higher scores of externalizing behaviors, such as 
aggression, attention/hyperactivity, and oppositional or defiant behaviors, than the 
clinical cutoff (Oberlander, et al., 2007). In addition, exposure to both prenatal SSRIs 
and maternal depression can increase internalizing behaviors (depression, anxiety, and 
withdrawal) in 3 and 4 year olds (Oberlander, et al., 2010). Preclinical studies have 
also demonstrated that developmental SSRI exposure can have long term effect on 
affective-like behaviors in offspring with a well-documented increase in both anxiety- 
and depression-related behaviors, particularly in adult male offspring, after prenatal or 
early postnatal treatment with SSRIs (Ansorge, Zhou, Lira, Hen, & Gingrich, 2004; 
Karpova, Lindholm, Pruunsild, Timmusk, & Castren, 2009; Lisboa, Oliveira, Costa, 
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Venancio, & Moreira, 2007; Noorlander et al., 2008; Olivier et al., 2011; Popa, Lena, 
Alexandre, & Adrien, 2008; Smit-Rigter et al., 2012), however, this is not always the 
case and often minimal long-term effects of perinatal SSRI exposure has been 
reported (Nagano, Liu, Inagaki, Kawada, & Suzuki, 2012; Pereira-Figueiredo, 
Sancho, Carro, Castellano, & Lopez, 2014). It should be noted that the majority of 
these studies did not investigate the effect of perinatal SSRI exposure using a model 
of maternal depression.  
Interestingly, recent research is showing that developmental SSRI exposure 
can reverse the effects of maternal stress, as a model of maternal depression 
(O'Mahony et al., 2006), on depressive- and anxiety-like behaviors, at least in male 
rat offspring (Nagano, et al., 2012; I. Rayen, van den Hove, Prickaerts, Steinbusch, & 
Pawluski, 2011) suggesting a potentially beneficial effect of perinatal SSRI exposure 
on development. Using a model of maternal stress and depression with SSRI exposure 
also more closely mimics the clinical situation and allows for further understanding of 
the effects of maternal stress/depression and SSRIs on development. Much more 
research is needed in this area.   
The molecular pathways underlying the long-term behavioral effects of early-
life SSRI exposure on mood are poorly understood. Research has shown that there are 
significant changes in hippocampal plasticity after exposure to SSRIs in adolescent 
and adult rat offspring (Ine Rayen, Gemmel, Pauley, Steinbusch, & Pawluski, 2015; I. 
Rayen, et al., 2011) and it is likely that these effects are related to changes in brain-
derived neurotrophic factor (BDNF) as well as BDNF and tropomyosin-related kinase 
receptor B (TrkB) signaling pathways. BDNF is critically involved in the regulation 
of neuronal plasticity, and alterations of BDNF signaling have been extensively 
implicated in the pathophysiology and treatment of mood disorders such as anxiety 
and depression (Castren & Rantamaki, 2010). Accordingly, a recent study showed 
that early postnatal administration of fluoxetine, a popular SSRI used during the 
perinatal period, could induce long-lasting behavioral impairment, accompanied with 
changes in hippocampal BDNF mRNA levels in adult male mice (Karpova, et al., 
2009), BDNF protein levels in adult male rats (Nagano, et al., 2012) and global DNA 
methylation in the hippocampus (Toffoli et al., 2014). Similarly, epigenetic changes at 
the BDNF gene in adulthood have been associated with mood disorders (Boulle et al., 
2012). Furthermore, serotonin transporter (5-HTT) knockout rats, which display high 
levels of serotonin (5HT), have lower levels of hippocampal BDNF, concomitant with 
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epigenetic dysregulation at the BDNF gene – i.e. increased DNA methylation at 
BDNF promoters IV and VI (Molteni et al., 2010). Further work is needed to 
determine how long-term behavioral changes related to developmental SSRI exposure 
may modulate hippocampal BDNF signaling.  
The aim of the present study was to investigate the long-term molecular and 
behavioral consequences of developmental administration of fluoxetine. Since 
perinatal maternal stress and depression itself can have marked effects on the 
development of mood disorders and stress regulation (Maccari & Morley-Fletcher, 
2007; Van den Hove et al., 2013), it is important to investigate the effects of SSRIs 
using a model of maternal depression (Pawluski, 2012; Van den Hove et al., 2008). 
Hence, we explored the effects of maternal fluoxetine during a time of rodent neural 
development that is analogous to SSRI exposure to human neonates beginning during 
the third trimester (Romijn, Hofman, & Gramsbergen, 1991), using a well-established 
model of prenatal restraint stress in Sprague-Dawley rats (Van den Hove et al., 2006; 
Weinstock, 2008), and focused particularly on measures related to affective behaviors 
and regulation of hippocampal BDNF signaling in adult male offspring. We expected 
to see a long-term impact of developmental SSRI exposure on affect-related behavior 
as well as hippocampal BDNF signaling that would be modified when using a model 
of prenatal stress as a model of maternal depression (Leuner, Fredericks, Nealer, & 
Albin-Brooks, 2014).  
 
Methods 
Animals  
Experiments were approved by the Animal Ethics Board of Maastricht University in 
accordance with Dutch governmental regulations (DEC 2008-157 and 2008-158), the 
European Communities Council Directive (86/609/EEC). All efforts were made to 
minimize the pain and stress experienced by the animals, to minimize the number of 
animals used and to utilize alternatives to in vivo techniques, if available.  
Thirty-eight adult female Sprague-Dawley rats (250–300 g; Charles River 
Laboratories, France) and twenty adult male Sprague-Dawley rats (Charles River 
Laboratories, France) were used in the present study for breeding. These animals were 
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initially housed in pairs in opaque polyurethane bins (48 cm × 27 cm × 20 cm) with 
ad libitum access to rat chow (Sniff, The Netherlands) and tap water and were kept 
under standard laboratory conditions in a 12h:12h light/dark schedule (lights on at 
07:00h). Dams were bred by putting 1 female and 1 male together in a wire mesh cage 
and pregnancy was determined by observation of vaginal plugs (embryonic day 0 – 
E0). Dams were randomly assigned to stress or control groups on GD14 and restraint 
of dams in the stress group took place three times daily in transparent plastic cylinders 
under bright light for 45 min (between 8-10am, 12-2pm, 4-6pm) as previously 
described between GD15-GD21 (Van den Hove et al., 2005; Ward & Weisz, 1984). 
Stress during late pregnancy can result in postpartum depressive-like behavior in the 
dam (Leuner, et al., 2014; O'Mahony, et al., 2006; Smith, Seckl, Evans, Costall, & 
Smythe, 2004) and, thus, this paradigm was used to model aspects of maternal 
postpartum depression as previously described (Leuner, et al 2014).  
The day after birth (PD1) litters were culled to 5 males and 5 females (birth 
day = P0) and dams and litters were randomly assigned to one of two treatment 
groups: fluoxetine (5mg/kg/day) or vehicle, for a total of four groups offspring: (1) 
No stress + Vehicle (NS VEH) (n= 14), (2) No stress + Fluoxetine (NS FLX) (n= 13), 
(3) Prenatal Stress + Vehicle (PNS VEH) (n= 15), (4) PNS + Fluoxetine (PNS FLX) 
(n= 14). Weaning occurred on P21, followed by housing of litter groups in clear 
polyutherane bins (48cm x 27cm x 20cm). One week later offspring were housed in 
same sex litter pairs until sacrifice (P196). Offspring were housed in the reverse light 
cycle (lights off at 7am) beginning at least 2 weeks prior to behavioral testing. Only 
male offspring were used in the present study. Female offspring were used in an 
additional work (Boulle et al, under review). A maximum of two adult male offspring 
per litter were chosen at random and used in the present study. Additional offspring 
were used in other studies.  
 
Fluoxetine exposure 
Fluoxetine treatment to the dam was administered via osmotic minipumps (Alzet 
Osmotic pumps, 2ML4, Cupertino CA, USA) during the postpartum period as 
previously described (Oliveira et al., 2010; I. Rayen, et al., 2011).  Osmotic 
minipumps were implanted subcutaneously in the dorsal region (upper back) of the 
dam on P1 using mild isofluorane anesthesia. Implants took a maximum of 20 
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minutes and offspring were separated from their mother for a maximum of 20 
minutes, but were housed in the same room as the dam. Minipumps were filled with 
either fluoxetine (Fagron, Belgium) dissolved in vehicle (50% propylenediol in saline; 
5mg/kg/day), or with vehicle as previously described (Alahmed & Herbert, 2008; Ine 
Rayen, et al., 2015; I. Rayen, Steinbusch, Charlier, & Pawluski, 2013, 2014). 
Fluoxetine, and its active metabolite, norfluoxetine, are present in breast milk 
and can pass to offspring through lactation (Gentile, 2004, 2005; Gentile, Rossi, & 
Bellantuono, 2007; Kristensen, et al., 1999). Administration of fluoxetine in this 
method and during the early postpartum period results in detectable levels of 
fluoxetine and its active metabolite, norfluoxetine, in serum of mother and pups 
(Knaepen et al., 2013). These implants also reduce the effect of stress associated with 
repeated injections or oral gavage. Fluoxetine exposure to offspring occurred during a 
stage of neural development in rodents analogous to that of the third trimester and 
early postnatal period in humans (Romijn, et al., 1991).  
 
Behavioral testing 
On P140 adult male offspring were subject to behavioral tests in the following order; 
the open field test, elevated zero maze, the forced swim test and corticosterone 
response to stress. There was 1 week between tests. Testing occurred between 9am 
and noon in the reversed light cycle.  
The open field test (OFT). The OFT consisted of a square plexiglass base (100 x 100 
cm) with a black floor and transparent plexiglass walls as previously described (Van 
den Hove, et al., 2013). Immediately after the rat was placed in the centre of the open 
field, the movements of the rat were scored automatically for 5 minutes using a 
camera connected to a computerized system (Ethovision Pro, Noldus, The 
Netherlands). Testing was done under low light conditions. Both the time spent in the 
peripheral and central zones and total distance moved was scored.  
The elevated zero maze (EZM). The EZM consisted of a circular alley (diameter of 
100 cm; path width 10 cm) made from black plexiglass material that was transparent 
for infrared light and elevated 20 cm above the floor as previously described (Van den 
Hove, et al., 2013). For the test, the rat was placed into one of the open arms facing a 
closed arm of the apparatus. The movements of the rat were scored automatically 
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under dark conditions with a computerized system using an infrared video camera 
(Ethovision Pro, Noldus, The Netherlands). Time spent in the open part of the maze 
and total distance traveled were determined as described previously (Van den Hove, 
et al., 2013). An open arm entry was when the center of the animal’s body and front 
two paws entered an open arm. 
 
The forced swim test (FST). Testing in the FST used cylindrical plexiglass tanks (50 
cm tall, 20 cm in diameter) filled to a height of 30 cm with 25°C water. The 
movements of the rat were scored automatically with a computerized system 
(Ethovision Pro, Noldus, The Netherlands) during a 10 min session under low light 
conditions. Scored behaviors were ‘immobility’, which reflects no movement at all 
and/or minor movements necessary to keep the nose above the water; ‘mobility’, 
reflecting movement that correspond to swimming activity; and ‘strong mobility’, 
reflecting ‘escape behavior’ (e.g. climbing against the walls and diving). Settings 
within Ethovision were adjusted based on manually recorded sessions 
(immobility/mobility threshold: 12; mobility/strong mobility threshold: 16.5 (Strackx 
et al., 2009; Van den Hove, et al., 2013).  
Corticosterone response to stress. Corticosterone response to stress was tested by 
individually placing offspring in a type II (mouse) cage filled with 500 ml 25C 
water. Immediately after taking the rat from its home cage, a first baseline blood 
sample was collected via a saphenous vein puncture. Immediately after this first 
sample was taken, the rat was put in the cage filled with water for 20 min after which 
a second blood sample was taken. The animal was then returned to its home cage and 
left undisturbed for 40 min after which a final blood sample was taken. Experiments 
were performed in an isolated room between 09.00 and 13.00 h. 
Blood samples were kept on ice and centrifuged at 5000 rpm for 10 min at 4 
C.  Plasma was stored at -80C for determination of corticosterone levels. Samples 
on a subset of animals (n=5-6/group) were run in duplicate using a commercially 
available RIA kit for rat corticosterone (corticosterone I-125 for rats and mice, MP 
Biomedicals, Santa Ana CA, USA), as explained previously (Pawluski, Charlier, 
Lieblich, Hammond, & Galea, 2008). The average intra- and inter-assay coefficients 
of variation for all assays were below 10%. The assay had a sensitivity of 7.7 ng/mL. 
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Cross reactivity with metabolites is as follows; corticosterone 100%, 
desoxycorticosteorne 0.34%, Testosterone 0.10%, Cortisol 0.05%, Aldosterone 
0.03%, Progesterone 0.02%, Androstenedion and 5alpha-dihydrotestosteorne 0.01%. 
 
Histology.  
One week after the last behavioral test (PND 196), offspring were rapidly decapitated. 
Hippocampi were extracted, immediately frozen in liquid nitrogen and stored at -80C. 
For analysis, both hippocampi from the same animal were pooled together. 
 Quantitative reverse transcriptase PCR (qRT-PCR). BDNF/TrkB signaling has been 
reported as a central player in the mechanism of action of SSRI, as well as in 
neurodevelopment (Autry & Monteggia, 2012). Therefore, we chose to study a subset 
of genes involved at various levels in the hippocampal BDNF/TrkB signaling 
pathway and known to be implicated in antidepressant responses and/or psychiatric 
phenotypes (Duman & Voleti, 2012; Rivero et al., 2013; Stragier et al., 2014; Van den 
Hove, et al., 2013).  These genes are listed in Table 1.  
Total mRNA extraction was performed on hippocampal tissues using RNeasy lipid 
tissue mini kit (Qiagen, Venlo, The Netherlands). Following this, cDNA synthesis 
was performed using a First Strand cDNA synthesis kit (Fermantas International Inc. 
Canada) according to the manufacturer’s protocol. Amplification was performed 
using SYBR green I Master Mix (Roche Diagnostic, IN, USA). Selected genes and 
primer sequences are indicated in Table 1. Gene expression analysis was performed 
with the LightCycler 480 Real-Time PCR System (Roche Applied Science, IN, USA) 
and the conditions for the reaction involved 35 cycles in a fixed sequence of 95C for 
30 s, 62C for 15 s, and 72C for 15 s. Gene expression was normalized using HPRT 
and RS27A as reference genes. 
Statistical analysis 
Analysis of variance tests (ANOVAs) were computed on results of behavioral 
tests, and all histological measures with condition (prenatal stress/no stress) and 
treatment (fluoxetine/vehicle) as independent factors. A repeated measures ANOVA 
was done on corticosterone response to stress. Significant condition by treatment 
interaction effects were analyzed in more detail by a Fisher LSD post hoc test in order 
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to compare the individual groups. Statistical significance was assumed to exist at p< 
0.05. All statistics were carried out using SPSS software version 17 (SPSS Inc, USA). 
 
Results 
OFT. There was a significant condition x treatment interaction in the number of visits 
to the center of the open field (F(1,52)=5.04; p=0.029; Figure 1), with fluoxetine 
decreasing the number of visits to the center in naïve animals and increasing the 
frequency of visits to the center in prenatally stressed offspring (NS FLX < PNS FLX; 
p=0.024). Similarly, regarding the distance traveled within the open field, a tendency 
towards a condition x treatment interaction was observed (F(1,52)=3.49; p=0.067; 
Figure 1), indicating that fluoxetine exposure differentially affected distance traveled 
in NS versus PNS adult male offspring. There were no other significant differences 
between groups in additional measures such as the time spent in the centre of the 
OFT(Figure 1B and Table 3). 
EZM. There was strong trend toward a significant condition x treatment interaction 
regarding the distance traveled within the EZM F(1, 51)= 4.04; p=0.049; Figure 2), 
where developmental fluoxetine exposure tended to decrease the distance traveled in 
naïve animals, while it increased the distance traveled in animals exposed to PNS 
(p=0.093). There were no other significant differences between groups in measures of 
the EZM such as duration in the open or closed arms(Figure 2 and Table 3). 
FST. Among males, a significant effect of PNS on strong mobility was found 
(F(1,51)=4.09; p=0.048; Figure 3), indicating that PNS decreased escape-like 
behavior in this behavioral test. There were no other significant differences between 
groups in immobility or mobility (Figure 3). 
Corticosterone. As expected, there was a significant main effect of time on 
corticosterone levels in male offspring (F(2, 38)=62.750, p=.00001, n=5-6/group; 
Figure 4) showing that 20 min of restraint stress elevated plasma corticosterone 
levels. There were no other significant differences in corticosterone levels with treatment 
(0.2 < p <0.8).  
Hippocampal gene expression. There was a significant effect of fluoxetine treatment 
on BDNF IV and tropomyosin-related kinase receptor B (TrkB) mRNA levels 
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(F(1,51)=5.57; p=0.022 and F(1,51)=7.21; p=0.0098 respectively; Figure 5), 
indicating that developmental fluoxetine exposure decreased BDNF IV and TrkB 
mRNA levels in both non stressed and prenatal stressed animals. In addition, BDNF 
IV mRNA levels were decreased in animals exposed to prenatal stress (PNS VEH < 
NS VEH; p=0.041). There was also a tendency towards a stress x treatment 
interaction for BDNF IX mRNA levels (F(1,51)=4.30; p=0.056; see Figure 5). There 
were no other significant differences between groups in related genes investigates 
(Table 4) and no significant correlations.  
 
Discussion 
With the growing use of SSRI antidepressant medication during pregnancy and the 
postpartum period (Cooper, et al., 2007; Oberlander, et al., 2006) more work is 
needed to understand the long-term risks and benefits of early-life exposure to these 
medications. In this context, the aim of the present study was to investigate how early 
exposure to fluoxetine may alter the effects of maternal stress on anxiety and 
depression-like behaviors, as well as neurobiological measures related to these 
behavioral outcomes, in adult male offspring. Our main findings show that postnatal 
fluoxetine exposure, via the mother, differentially alters anxiety-like behavior by 
increasing anxiety in non-prenatally stressed offspring and decreasing anxiety in 
prenatally stressed offspring. Overall, developmental fluoxetine exposure  
significantly decreased BDNF IV and TrkB mRNA expression in the hippocampus, 
regardless of prenatal stress exposure. We also found that prenatal stress alone 
significantly decreased escape behaviors (strong mobility) in the forced swim test and 
significantly decreased BDNF IV mRNA expression in the hippocampus. Together, 
these data contribute to our understanding of the long-term programming effects of 
early-life exposure to prenatal stress and SSRIs on affect–related behaviors and 
hippocampal gene expression of BDNF and its receptor TrkB.  
 
Developmental fluoxetine exposure and affective behaviors 
 In the present study developmental fluoxetine exposure increased anxiety in 
non-stressed male offspring, supporting previous literature showing an increase in 
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anxiety behavior following perinatal exposure to SSRIs in adult male rodents 
(Ansorge, Morelli, & Gingrich, 2008; Ansorge, et al., 2004; Karpova, et al., 2009; 
Lee, 2009; Noorlander, et al., 2008; Olivier, et al., 2011; Smit-Rigter, et al., 2012). 
However, in adult male offspring exposed to fluoxetine after prenatal stress there was 
a significant decrease in anxiety, as measured by the open field test. This supports our 
previous work showing that postnatal fluoxetine exposure can reverse the effects of 
maternal prenatal stress on behavior and shows that the actions of earlylife exposure 
to fluoxetine can markedly differ when using a model of maternal stress/depression, a 
model which arguably more closely mimics the clinical situation.  
We also found that prenatal stress alone decreased escape behaviors of adult 
male offspring with no effects of developmental flouxetine exposure on depression-
related behaviors. These findings are in accordance with earlier work in prenatally 
stressed Sprague-Dawley rat offspring that reported a decrease in escape attempts in 
the forced swim after prenatal stress, with little effect on immobility (Van den Hove, 
et al., 2013). Clearly showing that prenatal stress alone can have a significant long-
term impact on depression-related behaviors in adult offspring. 
We did not find an effect of developmental exposure to fluoxetine on any 
depression-related measures in the present study. Previous work we have done in 
adolescent offspring showed that developmental fluoxetine exposure reversed the 
effect of maternal stress on depression-related behavior, as measured by the FST 
(Rayen et al 2011). In addition, previous work has shown that developmental 
fluoxetine treatment, in non-stressed adult offspring, decreased immobility in the 
forced swim test (Karpova, et al., 2009). Discrepancies between our work and others 
may are likely due to methodological differences such as the timing and 
administration method of fluoxetine, age at testing, as well as species differences (rats 
versus mice). These findings suggest that developmental fluoxetine exposure has very 
little effect of depression-related behaviors in adult male offspring. However, more 
work is needed in this area using further tests of depression-related behaviors before 
firm conclusions can be made about the long-term impact of developmental exposure 
to SSRIs on depression.  
 
Developmental fluoxetine exposure and hippocampal BDNF signaling 
 14 
To further understand the long-term effects of developmental fluoxetine on molecular 
pathways that may underlie behavioral changes in adult male offspring, we examined 
hippocampal expression of BDNF, its high-affinity receptor TrkB and related 
signaling known to be involved in neuronal plasticity. Developmental fluoxetine 
exposure decreased hippocampus BDNF IV mRNA levels. During adulthood, the 
BDNF IV transcript is involved in the regulation of stress responses, and in the 
mechanism of action of antidepressants (Boulle, et al., 2012). Adult use of fluoxetine 
has been shown to increase BDNF levels (including BDNF IV mRNA levels) in 
cortico-limbic structures to induce antidepressant and anxiolytic effects in rodents 
(Martinowich, Manji, & Lu, 2007). Data from the current study showing that early 
life exposure to fluoxetine decreases hippocampal BDNF IV mRNA levels suggest 
that the molecular mechanisms mediating early-life versus adulthood fluoxetine 
interventions are distinct. This can partly be explained by the fact that during 
postnatal development, certain populations of neurons express a transient serotonergic 
phenotype that no longer exists at adulthood, and the modulation of this partial 5-HT 
system may interfere with the fine-tuning process of neuronal networks (Cases et al., 
1998; Gaspar, Cases, & Maroteaux, 2003). Moreover, fluoxetine interacts with 
several targets including 5-HT receptors (2A, 2C and 2B) and ion channels (Mostert, 
Koch, Heerings, Heersema, & De Keyser, 2008), as well as the 5-HTT. Hence, the 
distinct patterns of expression of these targetrs in early-life might be determinant in 
the long-term biological action of perinatal fluoxetine exposure.  
The present findings also show that developmental fluoxetine exposure 
decreased BDNF IX mRNA levels and TrkB mRNA levels in non-stressed male 
offspring. These findings, together with the observation that developmental fluoxetine 
exposure increased anxiety-like behavior in non-stressed male offspring, support that 
the notion that BDNF/TrkB signaling may play an important role in anxiety 
regulation (Chen et al., 2006; Martinowich, et al., 2007). 
 
Prenatal stress and hippocampal BDNF signaling. 
We also found that prenatal stress exposure further decreased BDNF IV mRNA levels 
in the hippocampus. This is in line with previous work showing the prenatal stress 
decreases expression of BDNF in the hippocampus of adult male offspring (Boersma 
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et al., 2014). However, others have found minimal or the opposite effect of prenatal 
stress on hippocampal BDNF signaling in offspring and these discrepancies may be 
due to the timing, duration and intensity of stress, as well as the species or strain of 
animals used (Karpova, et al., 2009; Neeley, Berger, Koenig, & Leonard, 2011; 
Roceri, Hendriks, Racagni, Ellenbroek, & Riva, 2002).  
Interestingly, a decrease in BDNF in the hippocampus has been reported in 
post-mortem brain analysis of suicide victims (Dwivedi et al., 2003; Pandey et al., 
2008). Rodent models of stress and depression during adulthood also showed a 
similar decrease of BDNF expression, including reduced levels of BDNF exon IV and 
exon IX (Fuchikami, Morinobu, Kurata, Yamamoto, & Yamawaki, 2009; 
Onishchenko, Karpova, Sabri, Castren, & Ceccatelli, 2008; Tsankova et al., 2006). 
BDNF expression is tightly regulated at the level of transcription with differential 
exon usage, suggesting a crucial role for the various transcripts in different, brain-
region-, cell-type- and intracellular location-specific processes and related brain 
functions (Baj, Leone, Chao, & Tongiorgi, 2011; Pruunsild, Kazantseva, Aid, Palm, 
& Timmusk, 2007).  
 
Conclusion and perspectives 
There is an increasing number of children exposed to SSRI medications during 
development (Cooper, et al., 2007; Oberlander, et al., 2006) and the long-term effects 
of such an exposure are still to be determined. Here, we show a long-term impact of 
maternal fluoxetine exposure on anxiety and hippocampal BDNF signaling in adult 
male offspring that can differ in the presence of maternal prenatal stress. This expands 
previous work that we, and others, have done exploring the long-term impact of early 
exposure of SSRIs on neurobehavioral development in male and female offspring, 
particularly using a model of maternal stress and depression (Ishiwata, Shiga, & 
Okado, 2005; Nagano, et al., 2012; Pawluski, 2012; Ine Rayen, et al., 2015; I. Rayen, 
et al., 2011). Our data support the idea that exposure to SSRI medications during 
development may have long-term consequences on neurodevelopment and affect-
related behaviors in adulthood, which may be attributed, at least in part, to 
reprogramming of signaling pathways implicated in neuronal plasticity. 
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Figure Captions 
Figure 1. Mean (±SEM) measure of A) Frequency of central entries, B) Time in 
the centre, and C) Total distance moved in the open field test (OFT). n=13-15 rats 
per group. *p < 0.05; Two-way ANOVA, Fisher LSD post hoc test. NS = no stress, 
PNS = prenatal stress, VEH = vehicle, FLX = fluoxetine. 
Figure 2. Mean (±SEM) measure of A) Time in the open areas and B) Total 
distance moved in the elevated zero maze (EZM). n=13-15 rats per group. *p < 
0.05; Two-way ANOVA. NS = no stress, PNS = prenatal stress, VEH = vehicle, FLX 
= fluoxetine. 
Figure 3. Mean (±SEM) measure of A) Immobility, B) Mobility, C) Strong 
mobility in the forced swim test (FST).  n=13-15 rats per group. *p < 0.05; **p < 
0.01; Two-way ANOVA, Fisher LSD post hoc test. NS = no stress, PNS = prenatal 
stress, VEH = vehicle, FLX = fluoxetine. 
Figure 4. Mean (±SEM) plasma corticosterone level s(ng/ml). n=5-6 rats per 
group. *p < 0.05 indicating corticosterone elevated after stress. NS = no stress, PNS = 
prenatal stress, VEH = vehicle, FLX = fluoxetine. 
Figure 5. Mean (±SEM) hippocampal mRNA expression of A)BDNF IV, 
B)BDNF IX, and C) TrkB. Data expressed as fold changes as compared to naïve 
animals (NS VEH) n=13-14 rats per group. *p < 0.05; Two-way ANOVA, Fisher 
LSD post hoc test. NS = no stress, PNS = prenatal stress, VEH = vehicle, FLX = 
fluoxetine. 
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